A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis
et al., Pharmaceuticals, doi:10.3390/ph15010078
, A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of.., Pharmaceuticals, doi:10.3390/ph15010078
PSM retrospective 3,712 hospitalized patients in Spain, showing lower mortality with existing use of azithromycin, bemiparine, budesonide-formoterol fumarate, cefuroxime, colchicine, enoxaparin, ipratropium bromide, loratadine, mepyramine theophylline acetate, oral rehydration salts, and salbutamol sulphate, and higher mortality with acetylsalicylic acid, digoxin, folic acid, mirtazapine, linagliptin, enalapril, atorvastatin, and allopurinol.
|
risk of death, 31.0% higher, OR 1.31, p = 0.04, RR approximated with OR.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Monserrat Villatoro et al., 8 Jan 2022, retrospective, propensity score matching, Spain, peer-reviewed, 18 authors.
Abstract: pharmaceuticals
Article
A Case-Control of Patients with COVID-19 to Explore the
Association of Previous Hospitalisation Use of Medication on
the Mortality of COVID-19 Disease: A Propensity Score
Matching Analysis
Jaime Monserrat Villatoro 1 , Gina Mejía-Abril 2 , Lucía Díaz García 1 , Pablo Zubiaur 2 ,
María Jiménez González 3 , Guillermo Fernandez Jimenez 4 , Inés Cancio 4 , José Ramón Arribas 5 ,
Carmen Suarez Fernández 6 , Jesús Mingorance 7 , Julio García Rodríguez 7 , José Ramón Villagrasa Ferrer 8 ,
Antonio J. Carcas 1 , Jesús Frías 1 , Francisco Abad-Santos 2, * , Alberto M. Borobia 1, * , Elena Ramírez 1, *
and on behalf of the COVID@HULP Working Group and Other Collaborators from Hospital Universitario
de la Princesa †
1
2
Citation: Monserrat Villatoro, J.;
Mejía-Abril, G.; Díaz García, L.;
Zubiaur, P.; Jiménez González, M.;
3
4
Fernandez Jimenez, G.; Cancio, I.;
Arribas, J.R.; Suarez Fernández, C.;
5
Mingorance, J.; et al. A Case-Control
of Patients with COVID-19 to Explore
6
the Association of Previous
Hospitalisation Use of Medication on
7
the Mortality of COVID-19 Disease:
A Propensity Score Matching
8
Analysis. Pharmaceuticals 2022, 15, 78.
https://doi.org/10.3390/
ph15010078
Academic Editors: Alan J. Hibbitts
and Sofia A. Papadimitriou
Received: 21 December 2021
Accepted: 4 January 2022
Published: 8 January 2022
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affiliations.
Copyright: © 2022 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
*
†
Clinical Pharmacology Department, La Paz University Hospital-IdiPAZ, Universidad Autónoma de Madrid,
28046 Madrid, Spain; jaimemonserratvillatoro@gmail.com (J.M.V.); ldiazg@salud.madrid.org (L.D.G.);
antonio.carcas@uam.es (A.J.C.); jesus.frias@uam.es (J.F.)
Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando,
Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La
Princesa (IP), 28006 Madrid, Spain; ginapaola.mejia@salud.madrid.org (G.M.-A.);
pablo.zubiaur@salud.madrid.org (P.Z.)
Clinical Trial Unit, La Paz University Hospital-IdiPAZ, 28046 Madrid, Spain; jimenezglezmaria@gmail.com
Medical Information Unit, Instituto de Investigación Sanitaria La Princesa (IP), Hospital Universitario de
La Princesa, 28006 Madrid, Spain; gfjimenez@salud.madrid.org (G.F.J.); Ines.Cancio@dxcfds.com (I.C.)
Internal Medicine Department, La Paz University Hospital-IdiPAZ, Universidad Autónoma de Madrid,
28046 Madrid, Spain; joser.arribas@salud.madrid.org
Internal Medicine Department, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid,
28006 Madrid, Spain; csuarezf@salud.madrid.org
Microbiology Department, La Paz University Hospital-IdiPAZ, 28046 Madrid, Spain;
jesus.mingorance@idipaz.es (J.M.); jgarciarodriguez@salud.madrid.org (J.G.R.)
Preventive Medicine Department, Hospital Universitario de La Princesa, Faculty of Medicine, Instituto de
Investigación Sanitaria La Princesa (IP), Universidad Autónoma de Madrid (UAM), 28006 Madrid, Spain;
joseramon.villagrasa@salud.madrid.org
Correspondence: francisco.abad@uam.es (F.A.-S.); alberto.borobia@salud.madrid.org (A.M.B.);
elena.ramirezg@uam.es (E.R.); Tel.: +34-915-202200..
Loading..
monserratvillatoro
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.